Objective. To determine clinical efficacy of the preparation «Aсtovegin», included in the complex therapy of patients with CHD. Material and methods. The research included patients aged from 30 to 60 with ischemic heart disease, i.e. stable stenocardia of I-III functional classes (chronic heart insufficiency of I-III functional classes according to NYHA classification and/or portinfarction cardiosclerosis). The average age at the moment of the examination was 55,03 ± 0,53. A total of 243 patients were examined, and of them, 216 patients were treated with aсtovegin. The statistic data were processed with the use of the standard set of statistic programs «Statistica», 6,0 (StatSoft, USA). Results. An earlier stabilization of stenocardia and relatively greater level of readaptation to physical activities as well as decrease of ejection fraction (EF) were observed in the patients treated with actovegin. The analysis of the biochemical blood values revealed that the treatment with this preparation led to a significant decrease in cholesterol, low- and very low-density lipoproteids. Conclusion. Actovegin in the complex therapy of patients with CHD stimulates contractile ability of cardiac muscle, has a positive effect on cardiac pumping function. Possessing an antihypoxic, insulin-like, cytoprotective and reperative effects, it corrects tissue metabolism, at the same time improving the biochemical blood values in the patients with CHD.

The clinical occurence of integrated surgical treatment of dilated cardiomyopathy is presented.

Objective. To discuss the clinical study of the development of cordarone-associated thyrotoxicosis. Results and discussion. The female patient D., born in 1956, had been under observation since 2007 on ciliary arythmia and artery hypertension. Sinus rhythm (SR) was restored and maintained by the application of cordarone. In March 2010 due to recrudescence the patient was hospitalized into the Department of Immunopathology and Allergology, Republican Research Center for Radiation Medicine and Human Ecology. After the clinical examination she was diagnosed with «cordarone-induced» thyrotoxicosis, probably, of type 2. It was recommended to stop using cordarone. Thyrotoxicosis was managed with methylprednisolone, and antiarythmic therapy was conducted with sotalex, propranolol, propafenone, strofantine (with no effect), also electropulse therapy was provided (rhythm was restored). To administer supporting antiarythmic therapy, it was recommended to take alapenin and bisoprolol. In the sequel, the patient revealed euthyroidism, the level of thyroidal hormones was at a norm. However, later there were frequent paroxysms of atrium fibrillation, short-term paroxysm of ventricular tachycardia. The patient was sent to have a consultation at the Laboratory for Heart Rhythm Disturbances of the Republican Research Center «Cardiology». Conclusion. Thus, the above-mentioned clinical observation makes it possible to draw a conclusion that long-term intake of cordarone can change metabolism of thyroidal hormones and, possibly, the electrophysiological properties of heart.